Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16293605 | 0.84 | GRIN2D (0.41) | MAPK13CDK1PIM1DYRK1APIM3 | |
| SCHEMBL6666508 | 0.84 | MAPT (0.50) | MAPK13CDK1PIM1DYRK1APIM3 | |
| SCHEMBL10468270 | 0.81 | PGK1 (0.41) | DYRK1AGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL16294402 | 0.79 | EGLN1 (0.37) | CYP1A2CACNA1HAR | |
| SCHEMBL207659 | 0.74 | F7 (0.42) | DYRK1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL416318 | 0.73 | FABP6 (0.41) | GAAGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7068666 | 0.71 | CHRNA1 (0.31) | — | |
| SCHEMBL3103036 | 0.70 | NQO2 (0.43) | GRIN2DGRIN3BLMNAGRIN1GRIN2A | |
| SCHEMBL1387977 | 0.68 | — | — | |
| SCHEMBL11817928 | 0.68 | GRIN2D (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177611-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2021-10-06 | — | — | EP | claimed |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-16 | — | — | US | claimed |
| EP-3177611-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | Nuevolution A/S (DK) | 2017-06-14 | — | — | EP | claimed |
| WO-2016020295-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2016-02-11 | — | — | WO | claimed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | claimed |
| US-20230143643-A1 | LOW DK COPPER CLAD LAMINATE COMPOSITIONS | DESIGNER MOLECULES INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230095931-A1 | UV-CURABLE RESIN COMPOSITIONS SUITABLE FOR REDISTRIBUTION LAYERS | DESIGNER MOLECULES INC (US) | 2023-03-30 | — | — | US | disclosed |
| EP-4097756-A2 | UV-CURABLE RESIN COMPOSITIONS SUITABLE FOR REDISTRIBUTION LAYERS | Designer Molecules, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115362535-A | UV curable resin composition suitable for redistribution layers | 设计分子有限公司 | 2022-11-18 | — | — | CN | disclosed |
| US-20220226340-A1 | CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER | Facio Intellectual Property B.V. (NL) | 2022-07-21 | — | — | US | disclosed |
| US-20220213267-A1 | EXTREME HIGH TEMPERATURE STABLE ADHESIVES AND COATINGS | DESIGNER MOLECULES, INC | 2022-07-07 | — | — | US | disclosed |
| US-20220204696-A1 | PHENOLIC FUNCTIONALIZED POLYIMIDES AND COMPOSITIONS THEREOF | DESIGNER MOLECULES, INC | 2022-06-30 | — | — | US | disclosed |
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | HONG BORCHERNG | 2006-08-03 | — | — | US | disclosed |
| WO-2006041921-A2 | PREPARATION AND USES OF RHODANINE DERIVATIVES | AUSPEX PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1594835-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | Auspex Pharmaceuticals, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005049582-A1 | METHOD OF PREPARATION OF NOVEL NUCLEOSIDE ANALOGS AND USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-06-02 | — | — | WO | disclosed |
| EP-1141021-B1 | REMOVAL/PURIFICATION OF SERUM ALBUMINS | AMERSHAM BIOSCIENCES AB (SE) | 2004-09-08 | — | — | EP | disclosed |
| WO-2004064745-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| EP-0716856-B1 | Therapeutic uses of 2',5'-oligoadenylate derivatives | UNIV TEMPLE (US) | 2001-08-29 | — | — | EP | disclosed |
| US-4950764-A | HERBICIDES, BACTERICIDES, ANALGESICS, ANTIINFLAMMATORY AGENT | FUJI PHOTO FILM CO., LTD. (JP) | 1990-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | MTPN, CHRNA7, CHRNA10 | MAPK13 2164/4885CDK1 4281/4885PIM1 4701/4885 |
| US-20220226340-A1 | CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER | CSNK1A1, CSNK1G3, CSNK1G1 | MAPK13 419/4885CDK1 63/4885PIM1 555/4885 |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | PPARD, PPARG, RORC | MAPK13 2351/4885CDK1 667/4885PIM1 4133/4885 |
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | LSS, DHPS, CYP51A1 | MAPK13 2664/4885CDK1 2339/4885PIM1 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.